You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNateglinide
Accession NumberDB00731  (APRD00593)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.

Structure
Thumb
SynonymsNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Starlixtablet60 mgoralNovartis Pharmaceuticals Corporation2000-12-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Starlixtablet120 mgoralNovartis Pharmaceuticals Corporation2000-12-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nateglinidetablet60 mgoralWatson Laboratories, Inc.2011-03-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nateglinidetablet120 mgoralWatson Laboratories, Inc.2011-03-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nateglinidetablet, coated60 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-09-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nateglinidetablet, coated120 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-09-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nateglinidetablet, coated60 mgoralPar Pharmaceutical Inc.2009-09-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nateglinidetablet, coated120 mgoralPar Pharmaceutical Inc.2009-09-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nateglinidetablet, coated120 mgoralPhysicians Total Care, Inc.2011-05-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nateglinidetablet60 mgoralDr. Reddy's Laboratories Limited2009-09-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nateglinidetablet120 mgoralDr. Reddy's Laboratories Limited2009-09-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nateglinidetablet, coated60 mgoralAmerican Health Packaging2012-01-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nateglinidetablet, coated120 mgoralAmerican Health Packaging2012-01-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
FasticNot Available
StarsisNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
SDZ-DJN 608
ThumbNot applicableDBSALT000922
Categories
CAS number105816-04-4
WeightAverage: 317.4226
Monoisotopic: 317.199093735
Chemical FormulaC19H27NO3
InChI KeyOELFLUMRDSZNSF-YJEKIOLLSA-N
InChI
InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15?,16-,17-/m1/s1
IUPAC Name
(2R)-3-phenyl-2-{[4-(propan-2-yl)cyclohexyl]formamido}propanoic acid
SMILES
CC(C)C1CC[C@@H](CC1)C(=O)N[C@H](CC1=CC=CC=C1)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-acyl-aliphatic-alpha amino acids. These are alpha amino acids carrying a N-acylated aliphatic chain.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentN-acyl-aliphatic-alpha amino acids
Alternative Parents
Substituents
  • N-acyl-aliphatic-alpha amino acid
  • 3-phenylpropanoic-acid
  • Menthane monoterpenoid
  • Monoterpenoid
  • Monocyclic monoterpenoid
  • Aromatic monoterpenoid
  • Amphetamine or derivatives
  • Amino fatty acid
  • Fatty acyl
  • Benzenoid
  • Monocyclic benzene moiety
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.
PharmacodynamicsInsulin secretion by pancreatic β cells is partly controlled by cellular membrane potential. Membrane potential is regulated through an inverse relationship between the activity of cell membrane ATP-sensitive potassium channels (ABCC8) and extracellular glucose concentrations. Extracellular glucose enters the cell via GLUT2 (SLC2A2) transporters. Once inside the cell, glucose is metabolized to produce ATP. High concentrations of ATP inhibit ATP-sensitive potassium channels causing membrane depolarization. When extracellular glucose concentrations are low, ATP-sensitive potassium channels open causing membrane repolarization. High glucose concentrations cause ATP-sensitive potassium channels to close resulting in membrane depolarization and opening of L-type calcium channels. The influx of calcium ions stimulates calcium-dependent exocytosis of insulin granules. Nateglinide increases insulin release by inhibiting ATP-sensitive potassium channels in a glucose-dependent manner.
Mechanism of actionNateglinide activity is dependent on the presence functioning β cells and glucose. In contrast to sulfonylurea insulin secretatogogues, nateglinide has no effect on insulin release in the absence of glucose. Rather, it potentiates the effect of extracellular glucose on ATP-sensitive potassium channel and has little effect on insulin levels between meals and overnight. As such, nateglinide is more effective at reducing postprandial blood glucose levels than fasting blood glucose levels and requires a longer duration of therapy (approximately one month) before decreases in fasting blood glucose are observed. The insulinotropic effects of nateglinide are highest at intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release already stimulated by high glucose concentrations (greater than 15 mmol/L). Nateglinide appears to be selective for pancreatic β cells and does not appear to affect skeletal or cardiac muscle or thyroid tissue.
AbsorptionRapidly absorbed following oral administration prior to a meal, absolute bioavailability is estimated to be approximately 73%. Peak plasma concentrations generally occur within 1 hour of oral administration. Onset of action is <20 minutes and the duration of action is approximately 4 hours.
Volume of distribution

10 liters in healthy subjects

Protein binding98% bound to serum proteins, primarily serum albumin and to a lesser extent α1 acid glycoprotein
Metabolism

Hepatic, via cytochrome P450 isoenzymes CYP2C9 (70%) and CYP3A4 (30%). Metabolism is via hydroxylation followed by glucuronidation. The major metabolites have less antidiabetic activity than nateglinide, but the isoprene minor metabolite has antidiabetic activity comparable to that of nateglinide.

SubstrateEnzymesProduct
Nateglinide
Nateglinide metabolite M2/M3Details
Nateglinide metabolite M2/M3
Not Available
Nateglinide metabolite M11/M12Details
Nateglinide
Nateglinide metabolite M1Details
Nateglinide metabolite M1
Not Available
Nateglinide metabolite M11/M12Details
Nateglinide
Not Available
Nateglinide metabolite M7Details
Nateglinide metabolite M7
Not Available
Nateglinide metabolite M11/M12Details
Nateglinide
Nateglinide glucuronide and isomers (M4/M5/M6)Details
Route of eliminationUrine (83%) and feces (10%)
Half life1.5 hours
ClearanceNot Available
ToxicityAn overdose may result in an exaggerated glucose-lowering effect with the development of hypoglycemic symptoms.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nateglinide Action PathwayDrug actionSMP00453
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.7539
Caco-2 permeable-0.7148
P-glycoprotein substrateSubstrate0.6187
P-glycoprotein inhibitor INon-inhibitor0.8842
P-glycoprotein inhibitor IINon-inhibitor0.8604
Renal organic cation transporterNon-inhibitor0.8882
CYP450 2C9 substrateNon-substrate0.7192
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5103
CYP450 1A2 substrateNon-inhibitor0.9167
CYP450 2C9 substrateNon-inhibitor0.8412
CYP450 2D6 substrateNon-inhibitor0.9088
CYP450 2C19 substrateNon-inhibitor0.8764
CYP450 3A4 substrateNon-inhibitor0.8874
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8734
Ames testNon AMES toxic0.922
CarcinogenicityNon-carcinogens0.9354
BiodegradationNot ready biodegradable0.7779
Rat acute toxicity2.0362 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9881
hERG inhibition (predictor II)Non-inhibitor0.8425
Pharmacoeconomics
Manufacturers
  • Dr reddys laboratories ltd
  • Par pharmaceutical inc
  • Teva pharmaceuticals usa
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
Tabletoral120 mg
Tabletoral60 mg
Tablet, coatedoral120 mg
Tablet, coatedoral60 mg
Prices
Unit descriptionCostUnit
Starlix 120 mg tablet2.12USD tablet
Starlix 60 mg tablet2.01USD tablet
Nateglinide 120 mg tablet1.73USD tablet
Nateglinide 60 mg tablet1.66USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada21146781999-04-272014-02-01
Canada22718652003-10-142017-11-14
United States65591882000-09-152020-09-15
United StatesRE348781992-09-082009-09-08
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityPractically insolubleNot Available
logP2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00848 mg/mLALOGPS
logP3.59ALOGPS
logP4.03ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)4ChemAxon
pKa (Strongest Basic)-0.38ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area66.4 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity89.46 m3·mol-1ChemAxon
Polarizability35.57 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Michito Sumikawa, “Methods for producing nateglinide B-type crystals.” U.S. Patent US20030229249, issued December 11, 2003.

US20030229249
General ReferenceNot Available
External Links
ATC CodesA10BX03
AHFS Codes
  • 68:20.16
PDB EntriesNot Available
FDA labelDownload (56.5 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcarboseAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
AcetohexamideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Acetylsalicylic acidMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
AlbiglutideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
AlogliptinMay enhance the hypoglycemic effect of Hypoglycemic Agents.
BosentanMay decrease the serum concentration of CYP3A4 Substrates.
BromocriptineAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
BuforminMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
CanagliflozinMay enhance the hypoglycemic effect of Hypoglycemic Agents.
ChlorpropamideMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
ConivaptanMay increase the serum concentration of CYP3A4 Substrates.
DabrafenibMay decrease the serum concentration of CYP3A4 Substrates.
DapagliflozinAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
DasatinibMay increase the serum concentration of CYP3A4 Substrates.
DeferasiroxMay decrease the serum concentration of CYP3A4 Substrates.
DihydrotestosteroneMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.
DisopyramideMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
DulaglutideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
EltrombopagMay increase the serum concentration of OATP1B1/SLCO1B1 Substrates.
EmpagliflozinAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
ExenatideMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
FosaprepitantMay increase the serum concentration of CYP3A4 Substrates.
GliclazideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
GlimepirideMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
GlipizideMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
GliquidoneMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Glucagon recombinantMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
GlyburideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
inhaled insulinMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
Insulin AspartMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin DetemirMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin GlargineMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
Insulin GlulisineMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin LisproMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
Insulin RegularMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
Insulin, isophaneMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Insulin, porcineMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
IvacaftorMay increase the serum concentration of CYP3A4 Substrates.
LanreotideMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
LinagliptinMay enhance the hypoglycemic effect of Hypoglycemic Agents.
LiraglutideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
LULICONAZOLEMay increase the serum concentration of CYP3A4 Substrates.
MecaserminMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
MetforminAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
MifepristoneMay increase the serum concentration of CYP2C9 Substrates.
MiglitolAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
MitiglinideMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
MitotaneMay decrease the serum concentration of CYP3A4 Substrates.
OctreotideMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
OxandroloneMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.
PasireotideMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
PegvisomantMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
PentamidineMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
PhenforminMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
PioglitazoneMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
PramlintideAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
QuinineMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
RepaglinideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
RosiglitazoneAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
Salicylate-sodiumMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents.
SaxagliptinMay enhance the hypoglycemic effect of Hypoglycemic Agents.
SiltuximabMay decrease the serum concentration of CYP3A4 Substrates.
SimeprevirMay increase the serum concentration of CYP3A4 Substrates.
SitagliptinAntidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemic Agents.
SulfadiazineMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
SulfamethoxazoleMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
SulfisoxazoleMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
SulodexideMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
SunitinibMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
TeriflunomideMay increase the serum concentration of OATP1B1/SLCO1B1 Substrates.
TestosteroneMay enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.
TocilizumabMay decrease the serum concentration of CYP3A4 Substrates.
TolazamideMay enhance the hypoglycemic effect of other Hypoglycemic Agents.
TolbutamideMay enhance the hypoglycemic effect of Hypoglycemic Agents.
VildagliptinMay enhance the hypoglycemic effect of Hypoglycemic Agents.
Food Interactions
  • Take upto 30 minutes before meals.

Targets

1. ATP-binding cassette sub-family C member 8

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
ATP-binding cassette sub-family C member 8 Q09428 Details

References:

  1. Hu S, Wang S, Fanelli B, Bell PA, Dunning BE, Geisse S, Schmitz R, Boettcher BR: Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther. 2000 May;293(2):444-52. Pubmed
  2. Sunaga Y, Gonoi T, Shibasaki T, Ichikawa K, Kusama H, Yano H, Seino S: The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431(1):119-25. Pubmed
  3. Hansen AM, Christensen IT, Hansen JB, Carr RD, Ashcroft FM, Wahl P: Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes. 2002 Sep;51(9):2789-95. Pubmed
  4. Chachin M, Yamada M, Fujita A, Matsuoka T, Matsushita K, Kurachi Y: Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP) channels. J Pharmacol Exp Ther. 2003 Mar;304(3):1025-32. Pubmed
  5. Norman P, Rabasseda X: Nateglinide: A structurally novel, short-acting, hypoglycemic agent. Drugs Today (Barc). 2001 Jun;37(6):411-426. Pubmed
  6. Dornhorst A: Insulinotropic meglitinide analogues. Lancet. 2001 Nov 17;358(9294):1709-16. Pubmed

2. Peroxisome proliferator-activated receptor gamma

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: agonist

Components

Name UniProt ID Details
Peroxisome proliferator-activated receptor gamma P37231 Details

References:

  1. Scarsi M, Podvinec M, Roth A, Hug H, Kersten S, Albrecht H, Schwede T, Meyer UA, Rucker C: Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Mol Pharmacol. 2007 Feb;71(2):398-406. Epub 2006 Nov 2. Pubmed

Enzymes

1. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 3A5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

4. Cytochrome P450 3A7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

5. Prostaglandin G/H synthase 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Prostaglandin G/H synthase 1 P23219 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

6. UDP-glucuronosyltransferase 1-9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 1-9 O60656 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

7. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Carriers

1. Serum albumin

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Serum albumin P02768 Details

References:

  1. Novartis. Starlix® (nateglinide) tablets prescribing information. East Hanover, NJ; 2009 Nov.

2. Alpha-1-acid glycoprotein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Alpha-1-acid glycoprotein 1 P02763 Details

References:

  1. Novartis. Starlix® (nateglinide) tablets prescribing information. East Hanover, NJ; 2009 Nov.

Transporters

1. Multidrug resistance-associated protein 4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Multidrug resistance-associated protein 4 O15439 Details

References:

  1. Uchida Y, Kamiie J, Ohtsuki S, Terasaki T: Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96. Epub 2007 Oct 16. Pubmed

2. Monocarboxylate transporter 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Monocarboxylate transporter 1 P53985 Details

References:

  1. Okamura A, Emoto A, Koyabu N, Ohtani H, Sawada Y: Transport and uptake of nateglinide in Caco-2 cells and its inhibitory effect on human monocarboxylate transporter MCT1. Br J Pharmacol. 2002 Oct;137(3):391-9. Pubmed

3. Solute carrier family 15 member 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 15 member 1 P46059 Details

References:

  1. Terada T, Sawada K, Saito H, Hashimoto Y, Inui K: Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol. 2000 Mar 24;392(1-2):11-7. Pubmed

4. Solute carrier family 15 member 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 15 member 2 Q16348 Details

References:

  1. Terada T, Sawada K, Saito H, Hashimoto Y, Inui K: Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol. 2000 Mar 24;392(1-2):11-7. Pubmed

5. Solute carrier family 22 member 6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 6 Q4U2R8 Details

References:

  1. Uwai Y, Saito H, Hashimoto Y, Inui K: Inhibitory effect of anti-diabetic agents on rat organic anion transporter rOAT1. Eur J Pharmacol. 2000 Jun 16;398(2):193-7. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11